Acceleron Pharma (XLRN) Said in Advanced Talks for $11 Billion Sale - Bloomberg

September 27, 2021 6:31 AM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Acceleron Pharma (NASDAQ: XLRN) is in advanced discussions to be acquired by a large pharmaceutical company for about $180 per share in cash, according to a report from Bloomberg after the market closed on Friday. The identity of the potential buyer couldn't be learned.

Bristol-Myers Squibb (NYSE: BMY) already owns a large stake in the company.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Hot M&A, Mergers and Acquisitions, Rumors